Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics

Respiratory Syncytial Virus Network (ReSViNET)

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

227 Citaten (Scopus)

Samenvatting

Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade include 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.

Originele taal-2Engels
Pagina's (van-tot)888-900
Aantal pagina's13
TijdschriftThe Lancet Respiratory Medicine
Volume3
Nummer van het tijdschrift11
DOI's
StatusGepubliceerd - 2015
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics'. Samen vormen ze een unieke vingerafdruk.

Citeer dit